611 related articles for article (PubMed ID: 16945988)
1. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
2. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype.
Numa AM; Abbott FS; Chang TK
Can J Physiol Pharmacol; 2007 Sep; 85(9):848-55. PubMed ID: 18066130
[TBL] [Abstract][Full Text] [Related]
3. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
5. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
6. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Rifkind AB; Lee C; Chang TK; Waxman DJ
Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
Ho PC; Abbott FS; Zanger UM; Chang TK
Pharmacogenomics J; 2003; 3(6):335-42. PubMed ID: 14597963
[TBL] [Abstract][Full Text] [Related]
8. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.
Court MH; Duan SX; Hesse LM; Venkatakrishnan K; Greenblatt DJ
Anesthesiology; 2001 Jan; 94(1):110-9. PubMed ID: 11135730
[TBL] [Abstract][Full Text] [Related]
12. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
15. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
[TBL] [Abstract][Full Text] [Related]
17. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
RamÃrez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of (-)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes.
Miyazawa M; Gyoubu K
Xenobiotica; 2007 Feb; 37(2):194-204. PubMed ID: 17484521
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
20. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.
Endo T; Ban M; Hirata K; Yamamoto A; Hara Y; Momose Y
Drug Metab Dispos; 2007 Mar; 35(3):476-83. PubMed ID: 17178767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]